BiomX Inc.

We are not currently a party to any material legal proceedings, other than as described below and in Notes 7 and 9 to the condensed consolidated interim financial statements included in this Quarterly Report.

*BiomX Ltd. insolvency.*On December 16, 2025, our former operating subsidiary, BiomX Ltd., commenced insolvency proceedings in Israel. On January 25, 2026, the Central District Court in Lod, Israel appointed a trustee over BiomX Israel. As a result of the appointment of the trustee and the related loss of control, we deconsolidated BiomX Israel effective February 4, 2026. As of June 30, 2026, our condensed consolidated balance sheet reflects a balance of approximately $1.3 million balance due to BiomX Israel, which may become subject to claims asserted by the trustee in the course of the insolvency proceedings. We are not able at this time to assess the likely outcome of the proceedings or to estimate the amount or range of any loss that may result.

*Adaptive Phage Therapeutics, LLC.*APT, our wholly owned subsidiary, is a defendant in an action filed by The Emmes Company, LLC in Maryland relating to services provided to APT’s legacy clinical programs. APT is being wound down and has engaged bankruptcy counsel in connection with an anticipated voluntary petition under Chapter 7 of the U.S. Bankruptcy Code. The Emmes action is pending in the Circuit Court for Montgomery County, Maryland (Case No. C-15-CV-26-003709) and seeks approximately $333,000 allegedly due for clinical trial services provided to APT; APT disputes the amount claimed, and its response is due on or about August 31, 2026. The Company is not a party to the action. The Board of Directors has authorized APT to file a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware; as of the date of this Quarterly Report the petition has not been filed, and the Company expects it to be filed shortly after the date hereof. Upon commencement of the Chapter 7 case, a trustee will assume control of APT and its remaining assets, and the Company expects to deconsolidate APT. The Company expects the Emmes claim to be addressed as a creditor claim in the Chapter 7 case.